| 1 |
23619284 | Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. | 2013 Jun 14 |
1 |
| 2 |
23047550 | Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro. | 2012 Nov 6 |
2 |
| 3 |
21290244 | Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. | 2011 Oct |
2 |
| 4 |
18175263 | Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. | 2008 Jan |
2 |
| 5 |
16902153 | Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. | 2006 Dec 1 |
4 |